SmithKline Beecham's Tagamet HB adds heartburn prevention claim.
This article was originally published in The Tan Sheet
Executive Summary
TAGAMET HB HEARTBURN PREVENTION CLAIM APPROVED BY FDA on Nov. 15. With the approval, SmithKline Beecham gains a new indication for its OTC H2 antagonist, which was approved for the treatment of heartburn in June ("The Tan Sheet" June 26, pp. 1-4). Tagamet HB was introduced in mid-August.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning